薄芝糖肽联合腹水浓缩回输对肝硬化合并自发性细菌性腹膜炎的临床研究  

Clinical study of Bozi glycopeptide joint ascites reinfusion in the treatment cirrhosis conbined with pontaneous bacterial peritonitis

作　　者：马鹏[1] 姚永刚[1] 谢明[1] 戴绍军[1] 邹传鑫[1] 沈雄山[1] 

机构地区：[1]华中科技大学同济医学院附属荆州医院消化内科,湖北荆州434020

出　　处：《中国临床药理学杂志》2015年第20期1999-2001,共3页The Chinese Journal of Clinical Pharmacology

基　　金：湖北省卫生厅科研指导性基金资助项目(JX6C-55)

摘　　要：目的评价薄芝糖肽联合腹水浓缩回输对肝硬化合并自发性细菌性腹膜炎的临床疗效和安全性。方法入选56例肝硬化合并自发性细菌性腹膜炎患者,随机分为对照组28例和试验组28例,试验组进行薄芝糖肽4 m L,每天1次,联合腹水浓缩回输治疗;对照组进行腹水浓缩回输治疗,均连续治疗2周。观察2组患者治疗前后脂多糖结合蛋白、肿瘤坏死因子-α和降钙素原水平,肝功能,并观察疗效和并发症情况。结果治疗后,2组患者脂多糖结合蛋白、肿瘤坏死因子-α和降钙素原水平均明显降低(P<0.05),且试验组明显低于对照组(P<0.05)。治疗后,试验组与对照组谷丙转氨酶降低,白蛋白水平明显升高(P<0.05),且试验组谷丙转氨酶明显低于对照组,而白蛋白水平明显高于对照组(P<0.05)。试验组治疗总有效率为82.14%,高于对照组的53.57%(P<0.05)。试验组并发症发生率为7.14%,明显低于对照组的32.14%(P<0.05)。结论薄芝糖肽联合腹水浓缩回输可有效治疗肝硬化合并自发性细菌性腹膜炎,改善患者临床症状,提高治疗效果。Objective To investigated the effect and safety of Bozi glyco- peptide joint ascites reinfusion in the treatment cirrhosis conbined with pontaneous bacterial peritonitis. Methods A total of 56 cases of cirrhotic patients with spontaneous bacterial peritonitis were selected and divided into two groups. The control group （28 cases） were treated with ascites reinfusion while experiment group （28 cases ） were treated with Bozhi glycopeptide 4 mL joint ascites reinfusion for two weeks. Lipopolysaccha- ride- binding protein, tumor necrosis factor -ct and procalcitonin levels, liver function, complications were observed before and after treat- ment. Results Lipopolysaccharide -binding protein, tumor necrosis factor - c~ and procalcitonin levels of two groups patients all obviously re- duced （P 〈 0. 05 ）, and those of experiment group were significantly lower than the control group （ P 〈 0. 05 ）. Alanine aminotransferase levels of two groups obviously reduced with albumin levels increased （P 〈 0.05 ）, and alanine aminotransferase of the experiment group was significantly lower than that of control group, the albumin level was higher （P 〈 0. 05 ）. Total effective rate of the experiment group （82. 14% ） were significantly higher than that of control group （53.57%） （P 〈 O. 05 ）. The complication rate of the experiment group （7. 14% ） were significantly lower than that of control group （32. 14% ） （ P 〈 0. 05 ）. Conclusion Bozhi glycopeptide joint ascites reinfusion can effectively treat cirrhosis combined with spontaneous bacterial peritonitis and improve clinical symptoms that can not only improve treat- ment but also be safe.

关 键 词：薄芝糖肽 腹水浓缩回输 肝硬化 细菌性腹膜炎 

分 类 号：R575.2[医药卫生—消化系统] R459.5[医药卫生—内科学]